News - Millennium Pharmaceuticals, Oncology


Popular Filters

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma


Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Watson confirms Velcade patent challenge; Mylan debuts generic Nordette


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) on Friday confirmed that its subsidiary Actavis…

ActavisGenericsMarkets & MarketingMillennium PharmaceuticalsMylan LaboratoriesNordette 28North AmericaOncologyPatentsReproductiveTeva Pharmaceutical IndustriesVelcadeWatson Pharmaceuticals

Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders


Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting…

Ambit BiosciencesBiotechnologyIncyteMillennium PharmaceuticalsMLN9708NovartisOncologyPharmaceuticalquizartinibResearchruxolitinibTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris


Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

More highlights from ESMO Congress


In further news coming out at the European Society of Medical Oncology (ESMO) Congress taking place in…

AdcetrisAstellas PharmaBiotechnologydabrafenibGlaxoSmithKlineImmunoGenMedivationMillennium PharmaceuticalsOncologyPharmaceuticalResearchRocheSeattle GeneticsT-DM1Takeda Pharmaceuticalstrastuzumab emtansineXtandi

Takeda unit posts updated survival data with HL drug candidate Adcetris


USA based Millennium, a wholly owned oncology subsidiary of Takeda Pharmaceutical (TYO: 4502), yesterday…

AdcetrisMillennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda Pharmaceuticals

Millennium is first industry partner in collaboration to advance personalized medicine for multiple myeloma


The Multiple Myeloma Research Foundation (MMRF) t that it has entered into a multi-year collaboration…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda Pharmaceuticals

US FDA approves Seattle Genetics’ Adcetris to treat two types of lymphoma


Shares of US biotech firm Seattle Genetics Nasdaq: SGEN) gained 8% to $15.09 late Friday, after the US…

AdcetrisBiotechnologybrentuximabMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top